InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,480.27
(
0.29%
)
US TECH 100
19,098.10
(
-0.57%
)
Dow Jones
39,496.91
(
0.89%
)
Brent Oil
85.17
(
1.37%
)
Bitcoin
61,016.62
(
-3.39%
)
Post# of 252317
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 117769

Wednesday, 04/06/2011 4:42:37 PM

Wednesday, April 06, 2011 4:42:37 PM

Post# of 252317

Not all patients just those with CC genotype.

Understood. I just don’t think IL28B is a strong enough biomarker to legitimately use it in the way that was suggested in the editorial you cited.

I do think that IL28B status should be used but the other way around: not treat patients who will likely not respond to interferon.

Are you referring to the first-line setting?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up